{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:26:53Z","timestamp":1781224013238,"version":"3.54.1"},"reference-count":22,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"DOI":"10.1182\/bloodadvances.2024014875","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T21:01:47Z","timestamp":1742331707000},"page":"2431-2435","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Long-term outcomes of chemoimmunotherapy with obinutuzumab\/chlorambucil in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"9","author":[{"given":"Valentin","family":"Goede","sequence":"first","affiliation":[{"name":"1Department of Oncogeriatrics, St. Marien Hospital, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Fischer","sequence":"additional","affiliation":[{"name":"2Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology Cologne, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-6655","authenticated-orcid":false,"given":"Sandra","family":"Robrecht","sequence":"additional","affiliation":[{"name":"2Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology Cologne, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Giza","sequence":"additional","affiliation":[{"name":"2Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology Cologne, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-2236","authenticated-orcid":false,"given":"Martin J. S.","family":"Dyer","sequence":"additional","affiliation":[{"name":"3The Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Eckart","sequence":"additional","affiliation":[{"name":"4Oncology Practice, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-4650","authenticated-orcid":false,"given":"Lothar","family":"M\u03cbller","sequence":"additional","affiliation":[{"name":"5Oncology Practice, Leer, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-8595","authenticated-orcid":false,"given":"Luk\u00e1\u0161","family":"Smolej","sequence":"additional","affiliation":[{"name":"64th Department of Internal Medicine - Haematology, Charles University Faculty of Medicine, University Hospital, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-8575","authenticated-orcid":false,"given":"Nadine","family":"Kutsch","sequence":"additional","affiliation":[{"name":"2Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology Cologne, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Fink","sequence":"additional","affiliation":[{"name":"2Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology Cologne, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"2Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology Cologne, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany"},{"name":"8Cologne Cluster of Excellence in Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"26","key":"2025052708520321000_bib1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2025052708520321000_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"23","key":"2025052708520321000_bib3","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"2025052708520321000_bib4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"10232","key":"2025052708520321000_bib5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"2025052708520321000_bib6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2025052708520321000_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025052708520321000_bib8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"21","key":"2025052708520321000_bib9","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1200\/JCO.22.02283","article-title":"Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study","volume":"41","author":"Munir","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025052708520321000_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2025052708520321000_bib11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"key":"2025052708520321000_bib12","unstructured":"National Comprehensive Cancer Network. Guideline CLL\/SLL. Accessed 14 August 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1478."},{"issue":"21","key":"2025052708520321000_bib13","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"6505","key":"2025052708520321000_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.abb8008","article-title":"Binding mechanisms of therapeutic antibodies to human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"issue":"12","key":"2025052708520321000_bib15","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"2025052708520321000_bib16","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2025052708520321000_bib17","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2025052708520321000_bib18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2023-174750","article-title":"Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of elevate-TN","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"issue":"18","key":"2025052708520321000_bib19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025052708520321000_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/hematology.2024000656","article-title":"Risk-stratification in frontline CLL therapy: standard of care","volume":"2024","author":"Tausch","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"2025052708520321000_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2018-03-839688","article-title":"Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab","volume":"133","author":"Langerak","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2025052708520321000_bib22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2431\/2374392\/blooda_adv-2024-014875-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2431\/2374392\/blooda_adv-2024-014875-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:52:12Z","timestamp":1748350332000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2431\/536217\/Long-term-outcomes-of-chemoimmunotherapy-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014875","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,15]]}}}